Skip to main content

Table 3 Overview of studies evaluating different dCRT regimens for EC

From: Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus

Author (year) Number of patients Study design Histology Radiotherapy Simultaneous Chemotherapy Median overall survival Local failure Distant failure ≥ III° heamtologic toxicity
Ruppert, BN (2010) [11] 19 Retrospective 42% SCC 50.4–61.2 Gy;
daily dose 1.8–2 Gy
Paclitaxel
Carboplatin
1-year OS 68.4% 42.1% 10.5% 46.7% (neutropenia)
Haj Mohammad, N (2014) [12] 127 Retrospective 36% SCC 50.4 Gy (28 Fx.) Paclitaxel Carboplatin 17.1 months (inoperable patients)
17.4 months (irresectable tumors)
42% 44% 7% (leukopenia)
Noronha, V (2016) [13] 179 Retrospective 92.2% SCC Mean dose 58.7 Gy in 32 Fx. Paclitaxel Carboplatin 19 months (1-year OS: 70%) 32% 15% 49% (leukopenia)
Honing, J (2014) [14] 102 Retrospective 50% SCC Median dose 50.4 Gy, daily dose 1.8–2 Gy 1. Cisplatin
5-FU
2. Paclitaxel Carboplatin
1. 16.1 months
2. 13.8 months
1. 19%
2. 4%
Herskovic, A (1992) [15] 61 (combined treatment) Phase 3 84% SCC 50 Gy (25 Fx) Cisplatin 5-FU 12.5 months (1-year OS: 50%) 43% 22% (after one year) 48%
Minsky, BD (2002) [17] 218 Phase 3 86% SCC 1. 50.4 Gy
(28 Fx)
2. 64.8 Gy
(36 Fx)
Cisplatin 5-FU 1. 18.1 months
2. 13 months
1. 55%
2. 50%
1. 16%
2. 9%
This study 47 Retrospective 100% SCC 1. Median dose 54 Gy (30 Fx.)
2. Median dose 59.4 Gy (33 Fx.)
1. Cisplatin
5-FU
2. Paclitaxel
Carboplatin
1. 24.2 months (1-year OS: 72%)
2. Not reached after 18.2 months) (1-year OS 70%)
1. 48%
(36% after one year)
2. 36% (32% after one year)
1. 20% (8% after one year)
2. 27% (18% after one year)
1. 52%
2. 55%